News 2

D2d sites across the nation are now prescreening for people with prediabetes to join the D2d study.  To see if a site near you is now prescreening visit the Sites page. 

D2d becomes the first NIDDK-supported trial and only the fifth NIH-supported study to join the pilot phase of IRBShare.  IRBShare provides a multi-site IRB review model that utilizes shared review documents and a shared review process.

The study’s first annual Investigators’ Meeting was held in Bethesda, MD.  Over the course of two days, investigators and coordinators from all 20 D2d sites worked together to plan a successful launch for D2d.

The first Data Safety Monitoring Board meeting took place in Bethesda, MD where the DSMB, D2d study members, and NIDDK personnel reviewed participant safety issues.  

Tufts Medical Center received the UO1 cooperative agreement grant to study the affects of vitamin D in people with prediabetes.

Tufts Medical Center’s U01 grant application undergoes scientific peer review.

Tufts Medical Center submits a U01 cooperative agreement grant to NIH for funding to study the affects of vitamin D in people with prediabetes.

NIDDK External Evaluation Committee reviews D2d’s U34 planning phase progress.

Tufts Medical Center is awarded a U34 planning grant which will provide support, Federal programmatic involvement, and technical assistance for the initial development of the D2d clinical trial.

Tufts Medical Center submits a U34 planning grant to NIH for support in establishing a research team, tools for data management, the development of a trial design, and other essential elements necessary for a nationwide clinical trial.

Tufts Medical Center receives approval for the submission of a U34 planning grant for D2d.

NIDDK Large Studies Committee reviews preliminary concept of D2d study.

R01 grant for the Calcium & Vitamin D and Diabetes Mellitus (CaDDM) trial is awarded.  The Research Project (R01) grant is an award to support investigators’ projects based on the mission of the NIH.